Journal
DRUGS
Volume 70, Issue 4, Pages 433-442Publisher
ADIS INT LTD
DOI: 10.2165/11534540-000000000-00000
Keywords
-
Categories
Funding
- Abbott
- AstraZeneca
- Bristol-Myers Squibb
- Cephalon
- Eli Lilly
- GlaxoSmithKline
- Pfizer
- Repligen
- Wyeth
- AstraZeneca Pharmaceuticals
- National Institute of Mental Health
- National Alliance for Research in Schizophrenia and Depression
- NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH085919, R01MH077047] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The diagnosis of bipolar disorder (BD) in children is increasing, and often requires a comprehensive treatment plan to address a complex array of symptoms and associated morbidities. Pharmacotherapy, in combination with psychotherapeutic interventions, is essential for the treatment and stabilization of disrupted mood. Current evidence collectively demonstrates, by randomized controlled design, that atypical antipsychotics have efficacy for the treatment of acute manic or mixed symptoms in children and adolescents with BD. Additional longitudinal and biological studies are warranted to characterize the effects of atypical antipsychotics on all phases and stages of bipolar illness development in children and adolescents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available